Fibrinogen and fractional exhaled nitric oxide as potential markers of lung functional impairment in clinically stable non-cystic fibrosis bronchiectasis

Bronchiectasis treatments

Chair(s): Pieter Goeminne, Holly R. Keir

Session type: Poster session

Nikoleta Bizymi

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Safety, tolerability, pharmacokinetics(PK) and pharmacodynamics(PD) of HSK31858?a novel DPP-1 inhibitor in healthy volunteers?a phase I clinical trial

Weijie Guan

Abstract

Changes of QoL-B in bronchiectasis patients undergoing an outpatient intravenous antibiotic therapy; preliminary results from a tertiary European Multicenter Bronchiectasis Audit and Research Collaboration (EMBARC) centre.

Pia Ghosh

Poster

Abstract

Pseudomonas aeruginosa eradication (PAE) in bronchiectasis (BE) with oral ciprofloxacin treatment (OC)

Letizia Traversi

Poster

Abstract

Fibrinogen and fractional exhaled nitric oxide as potential markers of lung functional impairment in clinically stable non-cystic fibrosis bronchiectasis

Nikoleta Bizymi

Poster

Abstract

Related factors to non-invasive ventilation in patients with acute bronchiectasis exacerbation

Ines Moussa

Poster

Abstract

A citizen phage library for respiratory infection

Philip Mitchelmore

Poster

Abstract

Real-world use of the BEST score for IV antibiotic courses in bronchiectasis

Philip Mitchelmore

Poster

Abstract

Microbiology in inhaled antibiotic users with bronchiectasis: Data from the European Bronchiectasis Registry (EMBARC)

Charles Haworth

Poster

Abstract

The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis

Ricardo Jose Pereira De Matos Cordeiro

Poster

Abstract

Pseudomonas aeruginosa eradication in patients with bronchiectasis: data from the EMBARC registry

Mattia Nigro

Poster

Abstract

Beclomethasone-formoterol vs placebo for chronic cough in bronchiectasis: the FORZA randomised-controlled trial

Tjeerd Van Der Veer

Poster

Abstract

Healthcare costs and resources utilization in patients with bronchiectasis compared to matched cohorts with asthma and COPD: a population-based cohort study

Marta Nadalin

Poster

Abstract

Dipeptidyl peptidase-1 inhibition in bronchiectasis with eosinophilic endotype in the WILLOW trial

Carlos Fernandez

Poster

Abstract

Efficacy of inhaled tobramycin in adult patients with bronchiectasis and P. aeruginosa in sputum: a prospective observational study

Andreas M. Matthaiou

Poster

Abstract

Study design of a Phase 2 rollover trial of the novel cathepsin C inhibitor BI 1291583 in patients with bronchiectasis

Michal Shteinberg

Poster

Abstract

Nebulised Meropenem for prevention of Bronchiectasis Exacerbation

Iftikhar Nadeem

Poster

Abstract

Long-term High flow nasal cannula therapy in bronchiectasis

Francesca Simioli

Poster

Abstract

Impact of hypertonic agents on the solids concentration in patients with bronchiectasis. A post-hoc analysis

Victoria Alcaraz-serrano

Poster

Abstract

A single-centre audit of specialist Bronchiectasis care and outcomes at 12 months

Georgia Tooth

Poster

Abstract

Retrospective review of treatment approaches for Pseudomonas aeruginosa infections in patients with Primary Ciliary Dyskinesia: Insights from a Danish cohort

Mathias G. Holgersen

Poster

Abstract

The ERS International Congress 2023, Milan

#{title}